Scientists Simplifying Science
Donate
Facebook Twitter Instagram Linkedin
Club SciWri header

Onco-this-Week

SHARE THIS

Summary: Onco-this-Week is  back with another news loaded edition featuring priority review to Gilteritinib in R/R AML, Larotrectinib in NTRK+ solid tumors, Fast Track Designation to Fimepinostat in R/R DLBCL, Breakthrough designation to Crizotinib in previously treated mNSCLC with MET exon 14 alterations and ALK+ ALCL), and several late phase trials meeting primary endpoint (Chidamide + Exemestane in HER2neg HR+ breast cancer, IMPower 130 in 1L NSCLC, Durvalumab in PACIFIC trial, Ibrutinib + Obinutuzumab Ph III iLLUMINATE trial in 1L CLL patients). 

 

Cancer, Anyone?

by dn23.

From Visually.

This edition of Onco-this-Week is Sponsored by Nano-Tag Biotechnologies

 

Note from our Sponsor: “Our FluoTag-X series features multiple fluorophores per affinity probe. For maximal brightness, FluoTag-X4 products even contain a blend of probes recognizing different epitopes on the same target.To know more contact us.”

“NanoTag Biotechnologies is a German company founded in July 2015 by scientists with a strong background in biochemistry as well as quantitative super-resolution imaging. Situated in Göttingen, we are in constant exchange with scientists developing and applying tools for innovative cutting-edge research. The inspiring atmosphere created by leading scientists and an excellent network of entrepreneurship is an ideal breeding ground for our vision to produce thoroughly validated high-quality tools for life-sciences, biotechnology and bio-medical research. Currently, our portfolio mainly focuses on single-domain antibody-based affinity reagents (“Tags”) for biochemical and fluorescence-based applications. In the near future, we are going to expand our portfolio to enzymes, affinity resins and secondary reagents for various immunoassays (IP, IF, IHC, IHC-P, WB…). Feel free to contact us anytime to discuss custom projects.”

 

Cover image: [Courtesy: Felipe Opazo (CEO) Nano-Tag Biotechnologies]3Indirect immunostaining of PFA fixed mouse brain section with Chicken anti-MAP2 (SYSY cat. no. 188 006) and FluoTag® anti-Chicken IgY conjugated to Sulfo-Cyanin 5 (cat. no. N0702-SC5) (green). Nuclei have been visualized by DAPI staining (blue).(For more info click here)

DRUG APPROVALS

Pertuzumab + Trastuzumab + Chemotherapy combination secures EU approval in adjuvant settings in HER2+ early breast cancer patients at high risk of recurrence

“Despite advances in the treatment of HER2-positive early breast cancer, many people still have a recurrence and progress to an incurable stage. In the early breast cancer setting, where the ultimate goal is cure, it is critical that we continue building on existing therapies,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “Today’s approval is great news, as we believe the Perjeta-based regimen has the potential to make a significant impact on the lives of people with HER2-positive early breast cancer who are at high risk of recurrence. We are committed to working with EU member states to ensure the Perjeta-based regimen is available to eligible patients as soon as possible.”

“Some patients with early HER2-positive breast cancer are more likely to relapse than others, despite available treatments. Perjeta builds on the efficacy we have already seen with Herceptin and provides a clinically meaningful reduction in the risk of the breast cancer returning or death, for patients at high risk of recurrence,” explained José Baselga, MD, PhD, Physician-in-Chief, Memorial Hospital, Memorial Sloan Kettering Cancer Center. “The only setting where we can potentially cure HER2-positive breast cancer is at the early stage, so the availability of new treatment options is great news for patients.”

REGULATORY NEWS

Priority review granted to Larotrectinib in NTRK fusion positive solid tumors; PDUFA: Nov 26, 2018

“We are excited the larotrectinib NDA has been accepted by FDA and granted Priority Review status,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “Larotrectinib marks an important shift towards treating cancer based on the tumor’s genetics rather than its site of origin in the body.”

FDA accepted Cabozantinib sNDA submitted on basis of Ph III CELESTIAL data in previously treated advanced HCC; PDUFA date: Jan 14, 2019

“Patients with this aggressive form of advanced liver cancer urgently need new treatment options after they progress on first-line therapy,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “The acceptance of our sNDA filing for CABOMETYX is a critical step forward as we work to help address this unmet need, and we intend to work closely with the FDA as they review the application.”

Celltrion Completes Resubmission for Rituximab and Trastuzumab biosimilar candidates CT-P10 and CT-P6 to FDA for Review

Celltrion official said: “Celltrion is confident that CT-P10 and CT-P6, following the success of REMSIMA® (INFLECTRA®) around the globe, will be the alternative oncology treatment options for the patients in the U.S. with proven record of quality, efficacy and safety to the reference product at an affordable price.”

Ph III ATLANTIS trial of Lurbinectedin, PM1183 + doxorubicin in SCLC patients to continue without any changes as per IDMC recommendation

PharmaMar has announced that the Independent Data Monitoring Committee (IDMC) notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.

The IDMC’s recommendation came after an analysis of the safety data obtained with more than 500 patients treated in the trial. This pivotal randomized Phase III trial assesses the efficacy of PM1183 in combination compared with the standard treatment for this indication: investigator’s choice of either Topotecan or CAV (cyclophosphamide, doxorubicin, and vincristine).

Ph Ib/II study of daratumumab + atezolizumab in previously treated NSCLC patients to be terminated as per DMC recommendation

“While we are disappointed that the studies will be discontinued, Genmab fully supports Janssen’s decision as patient safety is paramount in drug development. We look forward to gaining a better understanding of the data upon further analysis. We are pleased that the development program for daratumumab remains expansive and continues to benefit patients with Multiple Myeloma” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Priority status granted to Gilteritinib in R/R AML patients based on Ph III ADMIRAL study results; PDUFA: Nov 29, 2018

“FLT3 mutations impact approximately 30 percent of AML patients and are often associated with poor survival outcomes. Many with this condition relapse after treatment or don’t respond to currently available treatments. Simply put, they need more options,” said Steven Benner, M.D., senior vice president and global therapeutic area head, Oncology Development, Astellas. “The FDA’s acceptance of this NDA, with Priority Review, represents a significant milestone for gilteritinib and Astellas in our mission to help AML patients and the physicians who treat them”.

Crizotinib receives breakthrough designation in previously treated mNSCLC with MET exon 14 alterations and ALK+ ALCL

“Biomarker-driven therapies have changed the way we treat cancer, helping to ensure that patients receive the right medicine for their disease,” said Mace Rothenberg, M.D., chief development officer, Oncology, Pfizer Global Product Development. “These Breakthrough Therapy designations for XALKORI exemplify our commitment to precision medicine development and delivering medicines that have the potential to transform the lives of patients whose cancers carry these genomic alterations.”

BLA submitted for Sacituzumab govitecan for the treatment of heavily pretreated mTNBC patients

“The treatment of TNBC clearly represents an area of high unmet medical need and there are currently only very limited treatment options for mTNBC patients,” said Michael Pehl, President and Chief Executive Officer. “Further, the BLA submission of sacituzumab govitecan represents a significant milestone for Immunomedics on our path to unlock the future promise of our unique ADC platform for patients and healthcare professionals. We greatly thank the patients that participated in our trials along with their caregivers, and look forward to working closely with the FDA.”

DMC observes decreased survival with Atezolizumab/Pembrolizumab monotherapy compared to chemo in low PD-L1 patients – enrollment halted

In two ongoing clinical trials (KEYNOTE-361 and IMVIGOR-130), the Data Monitoring Committees’ (DMC) early reviews found patients in the monotherapy arms of both trials with PD-L1 low status had decreased survival compared to patients who received cisplatin- or carboplatin-based chemotherapy. There was no change in the adverse event profile of Keytruda or Tecentriq. Both Merck, manufacturer of Keytruda, and Genentech, manufacturer of Tecentriq, have stopped enrolling patients whose tumors have PD-L1 low status to the Keytruda or Tecentriq monotherapy arms per the DMCs’ recommendations.

SEPCIAL STATUSES

Fast Track Designation to Fimepinostat in R/R DLBCL

“We are pleased with this Fast Track designation, which will enable us to accelerate the development of fimepinostat for patients with R/R DLBCL, including patients whose tumors have MYC alterations,” said Ali Fattaey, Ph.D., Chief Executive Officer of Curis. “Patients with this disease have a very poor prognosis and we are encouraged by the FDA’s recognition of the unmet need that may be addressed by fimepinostat, as well as the potential durable benefit that fimepinostat can provide for these patients. We expect to re-initiate enrollment this year as part of a pivotal study to assess fimepinostat’s efficacy in this patient population. As we work toward the start of this study, we are also continuing to lay the groundwork for potential registration of fimepinostat, which involves coordination with commercial product manufacturers as well as a potential diagnostic test.”

 

RESULTS

Nivolumab – Ipilimumab combination provided significant and sustained HQoL improvements in intermediate- and poor-risk advanced RCC patients in CheckMate-214 Study

“With CheckMate -214, for patients with advanced renal cell carcinoma, we have previously seen the efficacy benefit of Opdivo plus low-dose Yervoy across a number of measures, including overall survival, objective response rate and progression-free survival,” said David Cella, Ph.D., chair, Department of Medical Social Sciences, and director, Institute for Public Health and Medicine – Center for Patient-Centered Outcomes, Northwestern University Feinberg School of Medicine, Chicago. “What we now add with this analysis is evidence that patients treated with this Immuno-Oncology combination also reported significant improvements in disease-related symptoms, as well as positive changes to their physical, emotional and functional well-being.”

John O’Donnell, MPP, Ph.D., vice president, worldwide health economics and outcomes research, Bristol-Myers Squibb, said, “The analysis of patient-reported outcomes in CheckMate -214 is particularly relevant for patients with advanced renal cell carcinoma as it shows that the combination of Opdivo plus low-dose Yervoy not only provides therapeutic benefits over a current standard of care but it demonstrates improvements in patient health-related quality of life that were sustained over the two-year follow-up period. These results attest to our leadership in Immuno-Oncology and our commitment to providing physicians with treatment options that make a difference in patients’ lives.”

DCVax-L increases median survival of 1L GBM patients significantly in interim analysis

“These are just interim data, and the data may get either better or worse as they continue to mature” commented Linda Powers, the Company’s CEO. “However, the survival times we are seeing are encouraging, especially in light of how little progress has been made in decades in treatments for Glioblastoma.”

“We have noted a growing recognition in the immuno-oncology field of the exceptional heterogeneity and complexity of Glioblastoma, and the need for treatments to target multiple antigens on these tumors” Ms. Powers continued. “DCVax-L is designed to use Nature’s system to mobilize an anti-tumor immune response, targeting the full set of antigens on a patient’s tumor and doing so in a fully personalized way. We believe this approach is key to the clinical results we are seeing.”

“The safety profile of DCVax-L is also quite encouraging, with almost no serious adverse events related to the treatment, no necessity for additional drugs to manage side effects and no hospital in-patient stays as are often required with certain other kinds of immune cell therapies” Ms. Powers noted. “This safety profile is quite important to patients, and we believe it can also facilitate combining DCVax-L with a variety of other types of treatments.”

Ph III IMpower130 study met its co-primary endpoints of OS and PFS in 1L metastatic non-squamous NSCLC patients

“The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced non-squamous non-small cell lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “We will share these results with global health authorities with the goal of bringing this potential treatment option to people with this disease.”

Ph III trial of HDAC inhibitor Chidamide + Exemestane in HER2neg HR+ breast cancer patients met primary endpoint of PFS improvement

Shenzhen Chipscreen Biosciences Co., Ltd. also known as Chipscreen Biosciences’s lead innovative oral subtype-selective histone deacetylase (HDAC) inhibitor, Epidaza® (Chidamide), met primary endpoint  of progression-free survival improvement in a pivotal phase III clinical trial in combination with exemestane. Chidamide is already approved for recurrent and refractory peripheral T cell lymphoma in China. This is Chidamide’s second approval. This breast cancer trial is a randomized, double-blind, placebo controlled study which enrolled postmenopausal hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC) patients who failed previous tamoxifen and/or nonsteroidal aromatase inhibitor therapy.

Planned interim analysis of Ph 2 study of pracinostat + azacitidine in higher risk MDS patients successfully met patient retention threshold; study to continue

“Patients with higher risk MDS currently face limited treatment options and poor outcomes,” stated Ehab Atallah, M.D., Study Chair, Associate Professor of Medicine, Medical College of Wisconsin. “Given the substantial need among this patient group, I am very encouraged by my experience to date in this study investigating pracinostat in combination with azacitidine.  Frequently, higher risk MDS develops into AML. The potential to offer patients a novel combination therapy that is generally well tolerated with the prospect for improved outcomes in MDS and possibly AML is exciting.”

Durvalumab Ph III PACIFIC trial meets second co-primary endpoint of OS improvement too in unresectable stage III NSCLC patients

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The readout of positive overall survival data at the interim analysis of the PACIFIC trial provides additional compelling evidence of the clinical benefit that Imfinzi can offer patients in this earlier stage of lung cancer. We look forward to sharing these results with Health Authorities to support ongoing regulatory interactions and to update the Imfinzi label with these important data.”

Ofatumumab + Bendamustine combination failed to meet primary endpoint in Ph IIICOMPLEMENT A+B trial in iNHL patients

“We are disappointed that the ofatumumab treatment regimen did not meet the primary endpoint in this trial. The completion of this Phase III study, which began in 2010, would not have been possible without the generous participation of the patients and their families, and we are most grateful for this. The full data will be submitted for publication at a future medical conference and we hope that these will provide a better understanding of this result,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Ibrutinib + Obinutuzumab Ph III iLLUMINATE trial in 1L CLL patients met primary endpoint

“We are optimistic about the topline results from the iLLUMINATE study and the fact that IMBRUVICA plus obinutuzumab demonstrated marked improvement in progression-free survival compared to obinutuzumab plus chlorambucil, a combination which is currently recommended by the National Comprehensive Cancer Network guidelines as a Category 1 treatment,”2 said Danelle James, M.D., M.A.S., Head of Clinical Science, Pharmacyclics LLC, an AbbVie company. “Since its introduction nearly five years ago, IMBRUVICA has been regarded as an important treatment option for patients with CLL/SLL. As well, we now have long-term, five-year data in CLL. We are committed to researching the full potential of IMBRUVICA alone and in combination therapy across a range of B-cell blood cancers.”

“We’re pleased to see positive results for the combination of ibrutinib plus obinutuzumab. This chemotherapy-free combination represents a potential new treatment option for patients with chronic lymphocytic leukemia,” said John Gribben, M.D., leading investigator for the iLLUMINATE study and Professor of Medical Oncology, Barts Cancer Institute, London, United Kingdom. “It’s exciting to see the blood cancer treatment paradigm continue to evolve – each advance moves us one step closer to a better standard of care for these patients.”

Vicinium shows positive preliminary results in high-grade BCG-treated NMIBC patients

“High-grade NMIBC is a devastating cancer that typically occurs later in life and for which treatment options are limited. Over the last 30 years, our industry has seen little innovation for the treatment of this prevalent cancer. The current standard-of-care, BCG, works in many patients, but many will also eventually relapse. For those patients who relapse or who don’t respond at all, the standard alternative is radical cystectomy. In a cystectomy, the bladder is removed along with surrounding lymph nodes and other organs that contain cancer. I am very encouraged by both the safety and these three-month efficacy data with Vicinium, and I look forward to continuing to work with the Sesen Bio team to help bring forward this potential treatment as a safe and effective option for my patients,” said Rian Dickstein, M.D. F.A.C.S., chief of urology, University of Maryland Baltimore Washington Medical Center; medical director of GU oncology, Tate Cancer Center at The University of Maryland Baltimore Washington Medical Center; clinical assistant professor, Department of Surgery, University of Maryland School of Medicine; director, bladder cancer program, Chesapeake Urology; and an investigator in the VISTA Trial.

“The VISTA Trial three-month data are encouraging for our company and the patients with high-grade NMIBC who have been underserved for many years,” said Stephen Hurly, president and chief executive officer of Sesen Bio. “We have made tremendous progress over the last several years to get us to where we are today, and I am proud of what our team has accomplished. Our new name is a reflection of the journey we’ve taken to get to this point and represents our mission of improving lives. With 12-month data expected by mid-2019, we are continuing to advance Vicinium to assess its full potential in treating this devastating cancer.”

TRIAL STATUSES

Ph II study of HER-2-targeting ADC, DS-8201, to start in advanced HER2-overexpressing or HER2-mutated non-squamous NSCLC

“There is renewed interest in exploring alterations in the HER2 pathway as treatment targets for NSCLC and clinical research suggests a potential role for a HER2-targeting ADC agent,” said Gilles Gallant, BPharm, PhD, Vice President, Global Team Leader DS-8201, Oncology Research and Development, Daiichi Sankyo. “DS-8201 is specifically designed to target and deliver chemotherapy inside HER2-expressing cancer cells, and we are advancing it to phase 2 in non-small cell lung cancer as part of our broad program in multiple types of HER2-expressing tumors.”

GlycoMimetics announces pivotal trial of selectin inhibitor GMI-1271 (Uproleselan) in older, 1L AML patients fit for intensive chemotherapy

“The NCI’s support of this clinical development program in AML reflects a high-level of interest from the U.S.’s leading clinical investigators and oncology thought leaders,” noted Helen Thackray, M.D., FAAP, GlycoMimetics Senior Vice President, Clinical Development, and Chief Medical Officer. “Based on our Phase 2 data, we believe GMI-1271 has the ideal profile to become the possible foundation of treatment across the continuum of care in AML. This is an important collaboration for us as we seek to realize the full potential of this novel therapeutic.”

Ph I/IIb trial evaluating JNJ-68284528 BCMA-targeting CAR-T cells for the treatment of R/R Multiple Myeloma initiated

“We are committed to rapidly advancing JNJ-68284528, and we are pleased to initiate a global clinical development program to further evaluate this cell-based therapy,” said Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. “As we strive to eliminate multiple myeloma, we are hopeful that this BCMA targeted CAR-T therapy will play an important role in the treatment of this disease.”

Patient enrolment begins in high dose cohort of Ph Ib study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Marina Cools, Clinical Lead at eTheRNA, said: “We continue to make good progress with the E011-MEL study, our first clinical trial assessing a directly injectable TriMix formulation in cancer patients. We would like to thank investigators for their efforts throughout the study so far and we look forward to progressing the high dose cohort over the coming months.”

Marc Dechamps, Acting CEO of eTheRNA, commented: “We are pleased to announce this development in our Phase 1b study in melanoma, which is progressing well and will read-out in early 2019. New clinical studies will be initiated over the coming year to provide further support for our mRNA-based TriMix immunotherapies and the vast potential they have in cancer, not only in activating the immune system but also in targeting it to tumour cells.”

mutRAS neoantigen cancer vaccine, TG01, shows encouraging efficacy in pancreatic cancer patients on adjuvant therapy

Professor Daniel H. Palmer, University of Liverpool Cancer Research UK Experimental Cancer Medicine Centre, Liverpool, United Kingdom and lead investigator of the study, commented:  “Pancreatic cancer is a highly malignant, difficult to treat disease and there is a significant need for innovative new treatment approaches. The results from this study are promising and demonstrate that TG01 is generally well tolerated in combination with gemcitabine. We observe a high level of mutant RAS-specific immune activation, and the observed survival rate is encouraging compared with chemotherapy alone. It will now be important to assess the clinical efficacy of the TG01 and standard of care combination treatment in a randomized setting, and we look forward to take part in the development of this innovative immunotherapy going forward”.

Øystein Soug, Chief Executive Officer of Targovax commented: “These more mature survival data represent another important milestone for Targovax. The high rate of immune activation, combined with the encouraging survival data which compares well with the large ESPAC4 trial, further strengthens our belief that our mutant RAS neoantigen vaccine has potential to be a promising new treatment approach in combating mutant RAS tumors, which constitutes up to 30% of all cancers.”

COLLABORATIONS AND LICENSING DEALS

Syndax and Nektar Therapeutics to evaluate Entinostat + NKTR-214 in patients with PD-1 refractory melanoma

“We are excited to be working with Nektar as we build upon our strategy of establishing clinical collaborations to test novel combinations of entinostat with leading edge immune therapies,” said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. “Previous Phase 2 data with entinostat and high dose IL-2 in renal cell cancer1 and our promising preclinical data generated with NKTR-214, laid the scientific and clinical foundation for this collaboration. Working with Nektar allows us to increase the potential impact entinostat may have in the treatment of PD-1 refractory metastatic melanoma patients, and complements the exciting data we have seen when combining entinostat with KEYTRUDA® in a similar population.”

“The combination of NKTR-214 and entinostat demonstrated a unique synergy in our preclinical models which warrants further study in the clinic,” said Jonathan Zalevsky, Ph.D, Senior Vice President and Chief Scientific Officer of Nektar.

“Importantly, we observed elevated levels of cytokine-positive tumor-infiltrating cytotoxic T cells following treatment with the combination. We believe this important preclinical finding could translate to improved tumor responses in patients who have become refractory to checkpoint inhibitors. We look forward to working with Syndax as this combination advances into the clinic.”

Immuno-oncolytic reovirus, pelareorep, to be combined with pembrolizumab, bortezomib and dexamethasone for treatment of multiple myeloma patients

Oncolytics Biotech, currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a collaboration with the Keck School of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda®, Velcade® and dexamethasone, to treat multiple myeloma.  This study, facilitated by Dr. Kevin Kelly, Associate Professor of Clinical Medicine, is an extension of the current REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone to treat multiple myeloma and will be conducted at the USC Norris Comprehensive Cancer Center.  It will add Keytruda, Merck’s anti PD-1 therapy, to the regimen.

Antengene to develop and commercialize Karyopharm’s Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia

“This agreement with Karyopharm brings to our pipeline four promising, clinical-stage product candidates with broad applicability across multiple disease areas, with a particular focus in oncology, with the potential to help patients in a number of Asian territories. To complement the ongoing clinical development efforts by Karyopharm, Antengene may initiate additional clinical trials in diseases with high incidence in Greater China and other Asian regions,” said Jay Mei, MD, PhD, Chairman and Chief Executive Officer of Antengene.  “At Antengene, we are driven by a higher purpose and our goal is to become a market leader in developing innovative therapies that address unmet medical needs in the Asia Pacific region. We are delighted to partner with Karyopharm, a pioneering oncology company with a strong track record in the research and development of novel, targeted compounds, and we believe this transaction underscores our strong focus on and commitment to healthcare innovation.”

“Antengene is dedicated to developing novel, cutting-edge therapies and has strong clinical and regulatory expertise and capabilities in China and the other licensed Asian regions,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm.  “This strategic alliance adds to the impressive consortium of global Karyopharm partners who are actively advancing our novel oral drug candidates in these important markets, while allowing us to focus our internal resources on executing our late-phase selinexor trials and pursue regulatory approval in the United States and the European Union.  In particular, this collaboration for additional territories in Asia complements our existing partnership with Ono Pharmaceutical for selinexor and eltanexor in Japan, Taiwan, South Korea, Hong Kong and the ASEAN countries.”

 

Infographically speaking…

Lung Cancer Infographic

From Visually.

 

About the Author: 

Richa earned her PhD at the National Brain Research Centre, India. For her thesis, she worked on the dreaded Glioblastoma multiforme. That was her first in-depth exposure to academic research in cancer biology. After her PhD, she expanded her research experience by working in the field of immunology at UCLA, USA. After her return to India, Richa switched to a corporate setting but continued her engagement with the cancer field. She is currently loving her work, which affords her the opportunity to continue developing her knowledge in the biomedical field of cancer. Outside of work, she enjoys watching, identifying and photographing birds.

Editor and Blog Design:

Abhi Dey

Abhi graduated from the Molecular Biophysics Unit of IISc (Bangalore, India) in 2011. As a Biomedical Scientist, he has worked with all three life-forms in his 13-year research career, viz., particulate, unicellular and multicellular. He is currently an Assistant Scientist at Emory University (Atlanta, GA) studying mechanisms of tumor recurrence in kids with brain tumors. As a postdoctoral fellow, he was the recipient of two Young Investigator Awards from Alex Lemonade Stand Foundation (Philadelphia, PA) and Rockland Immunochemicals. His current research has been funded by Northwestern Mutual Foundation (Milwaukee, WI), CURE Childhood Cancer Foundation (Atlanta, GA) and American Association for Cancer Research (AACR).  When he is not on the bench you will find him spending time with his family or exploring the world through traveling and blogging.

Image Sources: Wikipedia and Twitter

The contents of Club SciWri are the copyright of PhD Career Support Group for STEM PhDs {A US Non-Profit 501(c)3}. (PhDCSG is an initiative of the alumni of the Indian Institute of Science, Bangalore. The primary aim of this group is to build a NETWORK among scientists, engineers and entrepreneurs).

This work by Club SciWri is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

 

Disclaimer: The authors and editors for Onco-this-week declare no financial benefits or remuneration from the sponsors. The sponsorships support the non-profit organization, PhD Career Support Group. The research conducted by authors and editors is a voluntary effort to popularize science for the public on behalf of PhD CSG.

This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

 

SHARE THIS

The contents of Club SciWri are the copyright of Ph.D. Career Support Group for STEM PhDs (A US Non-Profit 501(c)3, PhDCSG is an initiative of the alumni of the Indian Institute of Science, Bangalore. The primary aim of this group is to build a NETWORK among scientists, engineers, and entrepreneurs).

This work by Club SciWri is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Tags

Related articles

Latest from Club SciWri